ArticleCancer medicine2017
MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma.
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 63 citations in OpenAlex.
- Placental exosomal miR-372-3p drives preeclampsia progression by inducing mitochondrial damage in RVLM neurons.Cellular & molecular biology letters · 2026Article
- Pathology and Therapeutic Significance of Fibroblast Growth Factors.Targets (Basel) · 2025Article
- Establishment of a prognostic model toward lung squamous cell carcinoma based on mPhysiological genomics · 2023Article
- Feedback Modulation between Human INO80 Chromatin Remodeling Complex and miR-372 in HCT116 Cells.International journal of molecular sciences · 2023Article
- Review
- miR-338-3p acts as a tumor suppressor in lung squamous cell carcinoma by targetingCancer pathogenesis and therapy · 2023Article
- miR-372-3p is a potential diagnostic factor for diabetic nephropathy and modulates high glucose-induced glomerular endothelial cell dysfunction via targeting fibroblast growth factor-16.Archives of medical science : AMS · 2023Article
- miR-372-3p promotes preeclampsia progression by regulating twist1.Experimental and therapeutic medicine · 2022Article
- [MiR-372-5p regulates PI3K/AKT/CXCL12 signaling pathway by targeting PTEN to promote colorectal cancer cell metastasis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- LncRNA PITPNA-AS1/miR-223-3p/PTN axis regulates malignant progression and stemness in lung squamous cell carcinoma.Journal of clinical laboratory analysis · 2022Article
- Long Noncoding RNA ZFAS1 Protects HK-2 Cells against Sepsis-Induced Injury through Targeting the miR3723p/PPARJournal of healthcare engineering · 2022Article
- Knockdown of miR-372-3p Inhibits the Development of Diabetic Cardiomyopathy by Accelerating Angiogenesis via Activating the PI3K/AKT/mTOR/HIF-1Oxidative medicine and cellular longevity · 2022Article
- Article
- MiR-372-3p Functions as a Tumor Suppressor in Colon Cancer by Targeting MAP3K2.Frontiers in genetics · 2022Article
- MiR-497-5p down-regulates CDCA4 to restrains lung squamous cell carcinoma progression.Journal of cardiothoracic surgery · 2021Article
- Potential Biomarkers of miR-371-373 Gene Cluster in Tumorigenesis.Life (Basel, Switzerland) · 2021Review
- MicroRNA-155-5p promotes cell proliferation and invasion in lung squamous cell carcinoma through negative regulation of fibroblast growth factor 9 expression.Journal of thoracic disease · 2021Article
- MicroRNA-665 facilitates cell proliferation and represses apoptosis through modulating Wnt5a/β-Catenin and Caspase-3 signaling pathways by targeting TRIM8 in LUSC.Cancer cell international · 2021Article
- Comprehensive network analysis of different subtypes of molecular disorders in lung cancer.American journal of translational research · 2021Article
- Genomic relevance of FGF14 and associated genes on the prognosis of pancreatic cancer.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to study the role of miR-372-3p in lung squamous cell carcinoma (LSCC) cell proliferation and invasion by suppressing FGF9. RT-PCR was used to determine miR-372-3p and FGF9 mRNA expression in tissues and cells. Western blot was used to determine FGF9 expression in tissues and NCI-H520 cell line. Dual luciferase reporter gene assay was conducted to confirm that FGF9 can be directly targeted by miR-372-3p. MTT, colony formation assays were conducted to investigate the effects of ectopic miR-372-3p and FGF9 expression on NCI-H520 cell growth. Flow cytometry was used to analyze the influence of miR-372-3p and FGF9 expression on cell cycle distribution and apoptosis. Transwell assay was also conducted to see the effects of miR-372-3p and FGF9 expression on NCI-H520 cell invasiveness. MiR-372-3p was found significantly overexpressed in both LSCC tissues and cell lines, whereas FGF9 mRNA was found underexpressed in LSCC tissues. MiR-372-3p directly bound to wild-type FGF9 mRNA 3'UTR, therefore led to the reduction in FGF9 expression. The upregulation of FGF9 or the downregulation of miR-372-3p substantially retarded LSCC cell growth, mitosis, and invasion. MiR-372-3p enhanced LSCC cell proliferation and invasion through inhibiting FGF9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.